Lumexa Imaging Q2 2026: Net Income Turns Positive, Guidance Narrowed
LMRI sits 87% above its 52-week low of $6.45.
Summary
Lumexa Imaging turned profitable in Q2 2026 with net income of $2.7 million, up from a $7.2 million loss last year, and narrowed its full-year Adjusted EBITDA guidance.
Key Events · Earnings and Guidance · LMRI
-
Q2 Net Income Turns Positive
Net income of $2.7 million in Q2 2026, compared to a net loss of $7.2 million in Q2 2025, driven by lower interest expense after refinancing.
-
Revenue Growth of 5.1%
Consolidated revenues of $264.2 million, up from $251.4 million, with same-center advanced outpatient volume growth of 5.2%.
-
Adjusted EBITDA Guidance Narrowed
Full-year 2026 Adjusted EBITDA guidance narrowed to $235-$241 million from $234-$242 million, with midpoint unchanged at $238 million.
-
Adjusted EPS Reiterated
Full-year 2026 Adjusted EPS guidance reiterated at $0.71-$0.77 per share.
Analysis · LMRI · Industrial Applications And Services
Lumexa Imaging reported Q2 2026 net income of $2.7 million, a swing from a $7.2 million loss a year ago, driven by lower interest expense after refinancing. Revenue grew 5.1% to $264.2 million. The company narrowed its full-year Adjusted EBITDA guidance to $235-$241 million, keeping the midpoint unchanged. This is the first detailed financial disclosure since the refinancing, showing improved profitability and cash flow.
At the time of this filing, LMRI was trading at $12.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.45 to $19.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.